Han Po Lo, MD
Urology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 28
- 7 carriers
- Offices
- 2
Offices
2 locations · El Camino Health Medical Network LLC · County of Santa Clara
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
28 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lo’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
28 of 28 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G87196 · Current
Licensed to practise in California · since 2004 · expires 2027-09-30 · University of Alabama School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Forest Surgery Center LPAmbulatory Surgery Center · San Jose, CAOwner · accredited by JCAccreditation Renewed1 inspection, 1 with deficiencies · last 2012-09-18: Requirements Met
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$330,598
Medicare paid this office $330,598 for 794 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 730 | $174,809 | $111 |
| Diagnostic exam of bladder and urethra using an endoscope | 96 | $32,339 | $247 |
| New patient visit (45+ min) | 133 | $19,440 | $146 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $11,181 | None |
| Ultrasound measurement of bladder capacity after voiding | 627 | $11,155 | $11 |
See all 13 services
| Return visit (30+ min) | 730 | $174,809 | $111 |
| Diagnostic exam of bladder and urethra using an endoscope | 96 | $32,339 | $247 |
| New patient visit (45+ min) | 133 | $19,440 | $146 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $11,181 | None |
| Ultrasound measurement of bladder capacity after voiding | 627 | $11,155 | $11 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 572 | $10,380 | $15 |
| Electronic assessment of bladder emptying | 585 | $10,327 | $12 |
| Long return visit (40+ min) | 26 | $6,205 | $168 |
| Urinalysis, manual test | 700 | $4,153 | $3 |
| Simple bladder irrigation and/or instillation | 27 | $3,149 | $77 |
| Complete ultrasound scan behind abdominal cavity | 20 | $1,912 | $96 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $1,048 | $37 |
| Manual urinalysis test with examination using microscope, automated | 262 | $933 | $3 |
Procedures Medicare counted
| Prostate resection | 14 | More than 67% of doctors who do this |
Who their Medicare patients are
794 Original Medicare patients in 2024. Average age 77 · Under 65 2% · 85 and older 19% · Women 18% · Also on Medicaid 16% · Health risk score 1.19. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Diabetes 36% · Coronary heart disease 30% · Chronic kidney disease 29% · Cancer 27% · Atrial fibrillation 21% · Heart failure 14% · COPD 10% · Stroke 10% · Depression 9% · Dementia 8%.
The office billed $1,331,927, Medicare allowed $446,674 and paid $330,598; for 12,216 services of 64 kinds; $11,746 of it was for drugs given in the office and $318,852 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 794 | 12,216 | 77 | 1.19 | $1,331,927 | $330,598 |
| 2023 | 807 | 25,698 | 77 | 1.11 | $1,101,414 | $355,038 |
| 2022 | 787 | 16,616 | 77 | 1.18 | $977,898 | $321,748 |
| 2021 | 719 | 7,329 | 77 | 1.16 | $929,250 | $317,588 |
| 2020 | 665 | 4,738 | 77 | 1.23 | $877,459 | $265,142 |
| 2019 | 734 | 5,902 | 77 | 1.26 | $1,017,232 | $299,535 |
| 2018 | 711 | 5,652 | 77 | 1.31 | $975,835 | $282,244 |
| 2017 | 696 | 5,316 | 77 | 1.34 | $897,554 | $266,740 |
| 2016 | 705 | 4,972 | 77 | 1.33 | $837,032 | $242,835 |
| 2015 | 712 | 5,076 | 78 | 1.29 | $881,965 | $264,403 |
| 2014 | 787 | 5,676 | 77 | 1.27 | $881,061 | $271,600 |
| 2013 | 720 | 5,655 | 77 | 1.31 | $868,880 | $281,287 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Return visit (30+ min) | 750 | $183,341 | $109 |
| Diagnostic exam of bladder and urethra using an endoscope | 97 | $31,069 | $251 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $20,293 | None |
| New patient visit (45+ min) | 134 | $18,724 | $140 |
| Electronic assessment of bladder emptying | 628 | $11,774 | $12 |
| Ultrasound measurement of bladder capacity after voiding | 650 | $11,341 | $10 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 13 | $8,495 | $653 |
| Dilation of urethra using an endoscope | 12 | $6,653 | $333 |
| Long return visit (40+ min) | 30 | $6,474 | $170 |
| Complete ultrasound scan behind abdominal cavity | 42 | $4,919 | $112 |
| Manual urinalysis test with examination using microscope, automated | 773 | $4,828 | $3 |
| Short return visit (20+ min) | 11 | $4,092 | $82 |
| Biopsy of prostate gland | 12 | $2,896 | $241 |
| Simple bladder irrigation and/or instillation | 26 | $2,685 | $77 |
| Ultrasound scan of pelvic region through rectum | 12 | $1,764 | $147 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $1,714 | $34 |
| Ultrasonic guidance for needle placement | 12 | $699 | $58 |
2022: 16 services
| Return visit (30+ min) | 709 | $165,855 | $107 |
| Diagnostic exam of bladder and urethra using an endoscope | 86 | $28,446 | $254 |
| New patient visit (45+ min) | 132 | $19,096 | $145 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 24 | $18,051 | None |
| Electronic assessment of bladder emptying | 576 | $10,009 | $12 |
| Ultrasound measurement of bladder capacity after voiding | 610 | $9,671 | $10 |
| Long return visit (40+ min) | 40 | $7,682 | $167 |
| Dilation of urethra using an endoscope | 14 | $7,519 | $342 |
| Manual urinalysis test with examination using microscope, automated | 717 | $4,262 | $3 |
| Biopsy of prostate gland | 16 | $3,929 | $246 |
| Complete ultrasound scan behind abdominal cavity | 34 | $3,783 | $108 |
| Simple bladder irrigation and/or instillation | 28 | $3,106 | $78 |
| Ultrasound scan of pelvic region through rectum | 16 | $2,419 | $151 |
| New patient visit (60+ min) | 12 | $2,343 | $195 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $1,399 | $32 |
| Ultrasonic guidance for needle placement | 16 | $817 | $51 |
2021: 14 services
| Return visit (30+ min) | 650 | $166,711 | $113 |
| Diagnostic exam of bladder and urethra using an endoscope | 79 | $27,095 | $246 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 24 | $21,685 | None |
| New patient visit (45+ min) | 128 | $18,976 | $148 |
| Dilation of urethra using an endoscope | 19 | $9,806 | $350 |
| Electronic assessment of bladder emptying | 521 | $9,581 | $12 |
| Ultrasound measurement of bladder capacity after voiding | 547 | $8,941 | $10 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $7,213 | $656 |
| Complicated insertion of bladder tube | 14 | $4,417 | $152 |
| Manual urinalysis test with examination using microscope, automated | 649 | $4,040 | $3 |
| Long return visit (40+ min) | 20 | $3,708 | $169 |
| Complete ultrasound scan behind abdominal cavity | 25 | $2,684 | $107 |
| Simple bladder irrigation and/or instillation | 26 | $2,407 | $83 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 24 | $1,603 | $33 |
2020: 13 services
| Return visit (30+ min) | 612 | $126,021 | $92 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 21 | $26,867 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 74 | $22,656 | $216 |
| New patient visit (45+ min) | 88 | $11,716 | $133 |
| Electronic assessment of bladder emptying | 476 | $8,857 | $12 |
| Ultrasound measurement of bladder capacity after voiding | 502 | $7,942 | $10 |
| Dilation of urethra using an endoscope | 11 | $3,924 | $327 |
| Manual urinalysis test with examination using microscope, automated | 582 | $3,515 | $3 |
| Complicated insertion of bladder tube | 12 | $3,350 | $140 |
| Short return visit (20+ min) | 47 | $3,209 | $67 |
| Long return visit (40+ min) | 15 | $2,659 | $140 |
| Simple bladder irrigation and/or instillation | 24 | $2,378 | $77 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $1,780 | $32 |
2019: 15 services
| Return visit (30+ min) | 671 | $143,757 | $94 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $26,894 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 79 | $20,672 | $190 |
| New patient visit (45+ min) | 124 | $17,179 | $139 |
| Ultrasound measurement of bladder capacity after voiding | 576 | $12,814 | $13 |
| Electronic assessment of bladder emptying | 548 | $11,702 | $12 |
| Manual urinalysis test with examination using microscope, automated | 670 | $4,631 | $3 |
| Complete ultrasound scan behind abdominal cavity | 32 | $3,579 | $112 |
| Biopsy of prostate gland | 13 | $3,233 | $249 |
| Long return visit (40+ min) | 16 | $2,901 | $138 |
| Simple bladder irrigation and/or instillation | 25 | $2,423 | $76 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $1,564 | $31 |
| Ultrasound scan of pelvic region through rectum | 12 | $1,504 | $125 |
| Ultrasonic guidance for needle placement | 13 | $672 | $52 |
| Imaging of urinary tract following injection of a contrast agent | 11 | $308 | $24 |
2018: 17 services
| Return visit (30+ min) | 646 | $127,550 | $91 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $27,672 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 89 | $20,477 | $160 |
| Ultrasound measurement of bladder capacity after voiding | 560 | $17,562 | $16 |
| New patient visit (45+ min) | 128 | $17,245 | $135 |
| Electronic assessment of bladder emptying | 532 | $14,136 | $13 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 12 | $8,013 | $668 |
| Manual urinalysis test with examination using microscope, non-automated | 624 | $4,776 | $4 |
| Long return visit (40+ min) | 30 | $4,372 | $132 |
| Complete ultrasound scan behind abdominal cavity | 33 | $3,824 | $116 |
| Biopsy of prostate gland | 12 | $2,956 | $227 |
| Simple bladder irrigation and/or instillation | 23 | $2,637 | $73 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $2,025 | $119 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $1,717 | $31 |
| Ultrasound scan of pelvic region through rectum | 12 | $1,023 | $85 |
| Ultrasonic guidance for needle placement | 13 | $747 | $50 |
| Manual urinalysis test with examination using microscope, automated | 51 | $200 | $4 |
2017: 17 services
| Return visit (30+ min) | 615 | $121,240 | $90 |
| Ultrasound measurement of bladder capacity after voiding | 544 | $19,908 | $19 |
| Diagnostic exam of bladder and urethra using an endoscope | 91 | $19,892 | $159 |
| New patient visit (45+ min) | 124 | $17,450 | $141 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $16,069 | None |
| Electronic assessment of bladder emptying | 517 | $12,953 | $13 |
| Manual urinalysis test with examination using microscope, non-automated | 629 | $5,229 | $4 |
| Long return visit (40+ min) | 34 | $5,098 | $134 |
| Biopsy of prostate gland | 13 | $3,065 | $236 |
| Simple bladder irrigation and/or instillation | 28 | $2,652 | $72 |
| Complete ultrasound scan behind abdominal cavity | 21 | $2,290 | $109 |
| Short return visit (20+ min) | 14 | $1,453 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,342 | $122 |
| Ultrasound scan of pelvic region through rectum | 13 | $1,257 | $97 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $1,090 | $32 |
| Ultrasonic guidance for needle placement | 14 | $884 | $59 |
| Instillation of anti-cancer drug into bladder | 11 | $402 | $31 |
2016: 12 services
| Return visit (30+ min) | 630 | $111,379 | $86 |
| Diagnostic exam of bladder and urethra using an endoscope | 84 | $20,615 | $186 |
| Ultrasound measurement of bladder capacity after voiding | 554 | $17,109 | $17 |
| New patient visit (45+ min) | 118 | $16,299 | $138 |
| Electronic assessment of bladder emptying | 521 | $11,987 | $13 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $8,066 | $733 |
| Manual urinalysis test with examination using microscope, non-automated | 640 | $5,023 | $4 |
| Long return visit (40+ min) | 24 | $3,750 | $129 |
| Dilation of urethra using an endoscope | 11 | $3,258 | $251 |
| Simple bladder irrigation and/or instillation | 23 | $2,127 | $76 |
| Complete ultrasound scan behind abdominal cavity | 19 | $1,950 | $103 |
| Short return visit (20+ min) | 24 | $1,786 | $60 |
2015: 13 services
| Return visit (30+ min) | 617 | $106,834 | $91 |
| Diagnostic exam of bladder and urethra using an endoscope | 81 | $20,277 | $193 |
| Ultrasound measurement of bladder capacity after voiding | 564 | $18,070 | $18 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $16,844 | None |
| New patient visit (45+ min) | 113 | $15,404 | $136 |
| Electronic assessment of bladder emptying | 530 | $13,440 | $15 |
| Short return visit (20+ min) | 142 | $10,641 | $55 |
| Manual urinalysis test with examination using microscope, non-automated | 627 | $4,908 | $4 |
| Simple bladder irrigation and/or instillation | 26 | $3,521 | $80 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,690 | $117 |
| Long return visit (40+ min) | 16 | $2,564 | $135 |
| Complete ultrasound scan behind abdominal cavity | 20 | $2,172 | $109 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $984 | $33 |
2014: 20 services
| Return visit (30+ min) | 445 | $60,896 | $90 |
| Short return visit (20+ min) | 503 | $49,238 | $61 |
| Diagnostic exam of bladder and urethra using an endoscope | 102 | $25,900 | $184 |
| Ultrasound measurement of bladder capacity after voiding | 614 | $19,418 | $19 |
| New patient visit (45+ min) | 134 | $18,103 | $135 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $14,740 | None |
| Electronic assessment of bladder emptying | 594 | $13,197 | $13 |
| Manual urinalysis test with examination using microscope, non-automated | 718 | $5,720 | $4 |
| Complete ultrasound scan behind abdominal cavity | 30 | $4,053 | $135 |
| Simple bladder irrigation and/or instillation | 33 | $3,805 | $75 |
| Complicated insertion of bladder tube | 11 | $3,651 | $122 |
| Dilation of urethra using an endoscope | 13 | $3,618 | $241 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,947 | $122 |
| New patient visit (30+ min) | 18 | $1,673 | $93 |
| Long return visit (40+ min) | 11 | $1,467 | $133 |
| Ultrasound scan of pelvic region through rectum | 12 | $1,202 | $92 |
| Short return visit | 12 | $1,001 | $40 |
| Ultrasonic guidance for needle placement | 12 | $935 | $72 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $926 | $32 |
| Urinalysis, manual test | 34 | $116 | $3 |
2013: 20 services
| Short return visit (20+ min) | 498 | $55,051 | $61 |
| Return visit (30+ min) | 297 | $43,799 | $94 |
| Diagnostic exam of bladder and urethra using an endoscope | 113 | $28,288 | $185 |
| New patient visit (45+ min) | 168 | $22,754 | $135 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $18,751 | None |
| Ultrasound measurement of bladder capacity after voiding | 545 | $17,547 | $19 |
| Electronic assessment of bladder emptying | 535 | $12,320 | $13 |
| Simple bladder irrigation and/or instillation | 26 | $6,911 | $79 |
| Manual urinalysis test with examination using microscope, non-automated | 658 | $5,798 | $4 |
| Ultrasonic guidance for needle placement | 18 | $4,175 | $209 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,938 | $119 |
| Biopsy of prostate gland | 17 | $3,372 | $198 |
| Complete ultrasound scan behind abdominal cavity | 26 | $3,309 | $127 |
| Dilation of urethra using an endoscope | 12 | $3,263 | $251 |
| Complicated insertion of bladder tube | 11 | $2,873 | $120 |
| Short return visit | 12 | $2,482 | $41 |
| Long return visit (40+ min) | 13 | $1,720 | $132 |
| Ultrasound scan of pelvic region through rectum | 18 | $1,435 | $72 |
| New patient visit (30+ min) | 14 | $1,315 | $94 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $1,283 | $33 |
Medicaid work
$1,326 in 2024
Medicaid paid $1,326 for 189 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 61 | $598 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 38 | $426 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 25 | $280 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 33 | $19 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 32 | $3 |
| 2024 | 189 | 5 | 17 | $1,326 |
| 2023 | 210 | 4 | 18 | $383 |
| 2022 | 126 | 3 | 15 | $375 |
| 2021 | 137 | 2 | 14 | $215 |
| 2020 | 45 | 2 | 16 | $0 |
| 2019 | 37 | 3 | 13 | $351 |
See the largest Medicaid services in earlier years
2023
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 26 | $200 |
| Return visit (30+ min) | 56 | $135 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 14 | $24 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 114 | $24 |
2022
| Return visit (30+ min) | 58 | $328 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 14 | $35 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 54 | $12 |
2021
| Return visit (30+ min) | 71 | $209 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 66 | $6 |
2020
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 16 | $0 |
| Return visit (30+ min) | 29 | $0 |
2019
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 12 | $296 |
| Complex uroflowmetry (eg, calibrated electronic equipment) | 12 | $54 |
| Return visit (30+ min) | 13 | $0 |
Drugs they prescribed that Part D paid
$523,930
Pharmacies billed $523,930 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (42 of 3,482) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
3,304 generic and fewer than 11 brand-name prescriptions · $523,930 in drug cost · 473 antibiotic prescriptions to 221 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 17 | $245,959 | $14,468 |
| Myrbetriq | 63 | $55,340 | $878 |
| Tamsulosin | 1,405 | $25,055 | $18 |
| Finasteride | 720 | $11,886 | $17 |
| Oxybutynin Chloride Er | 220 | $6,825 | $31 |
See all 23 drugs
| Xtandi | 17 | $245,959 | $14,468 |
| Myrbetriq | 63 | $55,340 | $878 |
| Tamsulosin | 1,405 | $25,055 | $18 |
| Finasteride | 720 | $11,886 | $17 |
| Oxybutynin Chloride Er | 220 | $6,825 | $31 |
| Nitrofurantoin Mono-Macro | 193 | $6,598 | $34 |
| Tolterodine Tartrate Er | 48 | $6,426 | $134 |
| Bicalutamide | 72 | $3,375 | $47 |
| Oxybutynin Chloride | 119 | $2,905 | $24 |
| Alfuzosin Hcl Er | 75 | $2,515 | $34 |
| Dutasteride | 24 | $1,077 | $45 |
| Cefdinir | 91 | $977 | $11 |
| Silodosin | 13 | $791 | $61 |
| Desmopressin Acetate | 15 | $749 | $50 |
| Trimethoprim | 23 | $729 | $32 |
| Terazosin | 27 | $632 | $23 |
| Doxazosin Mesylate | 12 | $321 | $27 |
| Sulfamethoxazole-Trimethoprim | 110 | $292 | $3 |
| Acetaminophen-Codeine | 38 | $291 | $8 |
| Cephalexin | 32 | $284 | $9 |
| Sildenafil Citrate | 35 | $219 | $6 |
| Amitriptyline | 16 | $173 | $11 |
| Solifenacin | 15 | $142 | $9 |
Year by year
| 2024 | 3,482 | 816 | 1% (42) | None | $523,930 |
| 2023 | 3,458 | 827 | 2% (55) | 6% | $385,757 |
| 2022 | 2,782 | 691 | 2% (47) | None | $370,415 |
| 2021 | 2,573 | 590 | 2% (39) | 8% | $137,131 |
| 2020 | 2,382 | 541 | 1% (26) | None | $108,326 |
| 2019 | 2,429 | 549 | 2% (45) | 10% | $199,372 |
| 2018 | 2,578 | 532 | 1% (22) | None | $305,682 |
| 2017 | 2,986 | 525 | 1% (43) | 9% | $127,805 |
| 2016 | 3,295 | 520 | 1% (42) | 6% | $118,482 |
| 2015 | 3,748 | 559 | 1% (39) | None | $150,105 |
| 2014 | 3,939 | 594 | 1% (33) | None | $155,619 |
| 2013 | 3,375 | 519 | 1% (45) | None | $156,533 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 26 drugs
| Xtandi | 14 | $210,557 | $15,040 |
| Myrbetriq | 83 | $59,815 | $721 |
| Tamsulosin | 1,323 | $36,100 | $27 |
| Finasteride | 618 | $12,179 | $20 |
| Tolterodine Tartrate Er | 71 | $11,701 | $165 |
| Nitrofurantoin Mono-Macro | 189 | $7,798 | $41 |
| Oxybutynin Chloride Er | 162 | $5,603 | $35 |
| Alfuzosin Hcl Er | 72 | $3,868 | $54 |
| Oxybutynin Chloride | 157 | $3,641 | $23 |
| Bicalutamide | 58 | $2,284 | $39 |
| Dutasteride | 24 | $2,109 | $88 |
| Cefdinir | 121 | $1,936 | $16 |
| Terazosin | 31 | $1,716 | $55 |
| Desmopressin Acetate | 20 | $1,524 | $76 |
| Bethanechol Chloride | 14 | $1,408 | $101 |
| Solifenacin | 16 | $950 | $59 |
| Trimethoprim | 35 | $871 | $25 |
| Nitrofurantoin | 15 | $723 | $48 |
| Sulfamethoxazole-Trimethoprim | 147 | $675 | $5 |
| Cephalexin | 65 | $519 | $8 |
| Silodosin | 13 | $510 | $39 |
| Sildenafil Citrate | 26 | $415 | $16 |
| Doxycycline Hyclate | 16 | $385 | $24 |
| Acetaminophen-Codeine | 51 | $251 | $5 |
| Amitriptyline | 12 | $179 | $15 |
| Doxazosin Mesylate | 11 | $141 | $13 |
2022: 19 drugs
| Xtandi | 14 | $197,595 | $14,114 |
| Myrbetriq | 78 | $60,116 | $771 |
| Tamsulosin | 1,180 | $26,646 | $23 |
| Finasteride | 461 | $9,490 | $21 |
| Tolterodine Tartrate Er | 77 | $8,460 | $110 |
| Nitrofurantoin Mono-Macro | 144 | $6,297 | $44 |
| Alfuzosin Hcl Er | 83 | $3,588 | $43 |
| Bicalutamide | 50 | $1,965 | $39 |
| Oxybutynin Chloride | 82 | $1,816 | $22 |
| Cefdinir | 71 | $1,473 | $21 |
| Oxybutynin Chloride Er | 31 | $1,297 | $42 |
| Trimethoprim | 49 | $1,150 | $23 |
| Dutasteride | 14 | $943 | $67 |
| Terazosin | 23 | $809 | $35 |
| Sulfamethoxazole-Trimethoprim | 163 | $723 | $4 |
| Doxazosin Mesylate | 17 | $533 | $31 |
| Cephalexin | 58 | $414 | $7 |
| Acetaminophen-Codeine | 47 | $251 | $5 |
| Sildenafil Citrate | 19 | $92 | $5 |
2021: 19 drugs
| Myrbetriq | 66 | $39,514 | $599 |
| Tamsulosin | 1,060 | $21,161 | $20 |
| Finasteride | 437 | $10,305 | $24 |
| Nitrofurantoin Mono-Macro | 198 | $9,134 | $46 |
| Tolterodine Tartrate Er | 40 | $3,727 | $93 |
| Alfuzosin Hcl Er | 74 | $3,122 | $42 |
| Oxybutynin Chloride Er | 45 | $1,798 | $40 |
| Dutasteride | 20 | $1,786 | $89 |
| Bicalutamide | 34 | $1,706 | $50 |
| Oxybutynin Chloride | 64 | $1,378 | $22 |
| Bethanechol Chloride | 12 | $1,276 | $106 |
| Trimethoprim | 66 | $849 | $13 |
| Sulfamethoxazole-Trimethoprim | 168 | $702 | $4 |
| Terazosin | 22 | $662 | $30 |
| Cefdinir | 48 | $532 | $11 |
| Doxazosin Mesylate | 15 | $529 | $35 |
| Cephalexin | 71 | $418 | $6 |
| Acetaminophen-Codeine | 38 | $225 | $6 |
| Ciprofloxacin | 16 | $101 | $6 |
2020: 18 drugs
| Myrbetriq | 52 | $27,028 | $520 |
| Tamsulosin | 980 | $19,584 | $20 |
| Finasteride | 460 | $9,470 | $21 |
| Nitrofurantoin Mono-Macro | 145 | $6,104 | $42 |
| Oxybutynin Chloride | 98 | $2,362 | $24 |
| Alfuzosin Hcl Er | 54 | $2,263 | $42 |
| Dutasteride | 20 | $2,021 | $101 |
| Oxybutynin Chloride Er | 57 | $1,894 | $33 |
| Trimethoprim | 95 | $1,303 | $14 |
| Bicalutamide | 30 | $1,292 | $43 |
| Doxazosin Mesylate | 18 | $1,171 | $65 |
| Bethanechol Chloride | 13 | $885 | $68 |
| Cefdinir | 20 | $846 | $42 |
| Sulfamethoxazole-Trimethoprim | 166 | $671 | $4 |
| Terazosin | 20 | $406 | $20 |
| Cephalexin | 59 | $319 | $5 |
| Ciprofloxacin | 17 | $154 | $9 |
| Acetaminophen-Codeine | 22 | $115 | $5 |
2019: 18 drugs
| Myrbetriq | 55 | $30,003 | $546 |
| Tamsulosin | 944 | $26,477 | $28 |
| Finasteride | 494 | $14,013 | $28 |
| Elmiron | 11 | $11,811 | $1,074 |
| Nitrofurantoin Mono-Macro | 113 | $5,139 | $45 |
| Oxybutynin Chloride Er | 63 | $3,011 | $48 |
| Oxybutynin Chloride | 87 | $2,586 | $30 |
| Alfuzosin Hcl Er | 52 | $2,237 | $43 |
| Dutasteride | 24 | $2,065 | $86 |
| Trimethoprim | 138 | $1,691 | $12 |
| Doxazosin Mesylate | 29 | $1,411 | $49 |
| Bicalutamide | 28 | $1,073 | $38 |
| Terazosin | 22 | $808 | $37 |
| Sulfamethoxazole-Trimethoprim | 160 | $742 | $5 |
| Bethanechol Chloride | 12 | $736 | $61 |
| Ciprofloxacin | 51 | $499 | $10 |
| Cephalexin | 47 | $278 | $6 |
| Acetaminophen-Codeine | 38 | $156 | $4 |
2018: 19 drugs
| Xtandi | 14 | $153,596 | $10,971 |
| Tamsulosin | 958 | $28,424 | $30 |
| Myrbetriq | 39 | $17,802 | $456 |
| Finasteride | 570 | $14,549 | $26 |
| Vesicare | 14 | $6,407 | $458 |
| Oxybutynin Chloride Er | 103 | $4,959 | $48 |
| Nitrofurantoin Mono-Macro | 84 | $3,982 | $47 |
| Oxybutynin Chloride | 111 | $3,309 | $30 |
| Alfuzosin Hcl Er | 73 | $2,685 | $37 |
| Dutasteride | 23 | $2,455 | $107 |
| Avodart | 11 | $2,141 | $195 |
| Trimethoprim | 170 | $2,125 | $12 |
| Bicalutamide | 49 | $1,901 | $39 |
| Doxazosin Mesylate | 33 | $1,543 | $47 |
| Terazosin | 35 | $797 | $23 |
| Sulfamethoxazole-Trimethoprim | 136 | $718 | $5 |
| Ciprofloxacin | 52 | $495 | $10 |
| Cephalexin | 46 | $278 | $6 |
| Acetaminophen-Codeine | 19 | $87 | $5 |
2017: 21 drugs
| Tamsulosin | 1,188 | $28,524 | $24 |
| Vesicare | 40 | $17,573 | $439 |
| Myrbetriq | 28 | $12,142 | $434 |
| Finasteride | 670 | $11,764 | $18 |
| Tolterodine Tartrate Er | 27 | $3,948 | $146 |
| Oxybutynin Chloride Er | 96 | $3,746 | $39 |
| Oxybutynin Chloride | 90 | $3,215 | $36 |
| Nitrofurantoin Mono-Macro | 84 | $3,099 | $37 |
| Avodart | 11 | $2,040 | $185 |
| Bicalutamide | 75 | $1,763 | $24 |
| Trimethoprim | 158 | $1,642 | $10 |
| Alfuzosin Hcl Er | 89 | $1,639 | $18 |
| Dutasteride | 28 | $1,485 | $53 |
| Doxazosin Mesylate | 34 | $1,364 | $40 |
| Sulfamethoxazole-Trimethoprim | 138 | $584 | $4 |
| Terazosin | 33 | $537 | $16 |
| Bethanechol Chloride | 12 | $501 | $42 |
| Cephalexin | 52 | $294 | $6 |
| Ciprofloxacin | 45 | $244 | $5 |
| Acetaminophen-Codeine | 31 | $132 | $4 |
| Hydrocodone-Acetaminophen | 12 | $58 | $5 |
2016: 20 drugs
| Tamsulosin | 1,333 | $32,088 | $24 |
| Vesicare | 52 | $20,610 | $396 |
| Finasteride | 722 | $11,840 | $16 |
| Oxybutynin Chloride Er | 172 | $6,645 | $39 |
| Myrbetriq | 15 | $5,016 | $334 |
| Potassium Citrate Er | 15 | $3,219 | $215 |
| Oxybutynin Chloride | 113 | $3,168 | $28 |
| Nitrofurantoin Mono-Macro | 64 | $3,145 | $49 |
| Avodart | 14 | $3,056 | $218 |
| Dutasteride | 39 | $2,511 | $64 |
| Bicalutamide | 110 | $2,312 | $21 |
| Alfuzosin Hcl Er | 100 | $2,301 | $23 |
| Doxazosin Mesylate | 41 | $1,641 | $40 |
| Trimethoprim | 94 | $1,151 | $12 |
| Ciprofloxacin | 151 | $880 | $6 |
| Terazosin | 61 | $783 | $13 |
| Sulfamethoxazole-Trimethoprim | 83 | $348 | $4 |
| Hydrocodone-Acetaminophen | 20 | $136 | $7 |
| Acetaminophen-Codeine | 22 | $134 | $6 |
| Cephalexin | 15 | $89 | $6 |
2015: 17 drugs
| Tamsulosin | 1,384 | $46,651 | $34 |
| Vesicare | 73 | $24,849 | $340 |
| Avodart | 76 | $19,629 | $258 |
| Finasteride | 859 | $11,681 | $14 |
| Oxybutynin Chloride Er | 235 | $9,590 | $41 |
| Enablex | 14 | $4,579 | $327 |
| Nitrofurantoin Mono-Macro | 83 | $3,460 | $42 |
| Alfuzosin Hcl Er | 163 | $3,348 | $21 |
| Oxybutynin Chloride | 113 | $2,941 | $26 |
| Bicalutamide | 130 | $2,932 | $23 |
| Doxazosin Mesylate | 63 | $2,271 | $36 |
| Ciprofloxacin | 212 | $1,250 | $6 |
| Trimethoprim | 89 | $1,161 | $13 |
| Terazosin | 70 | $817 | $12 |
| Acetaminophen-Codeine | 26 | $157 | $6 |
| Sulfamethoxazole-Trimethoprim | 24 | $101 | $4 |
| Hydrocodone-Acetaminophen | 13 | $64 | $5 |
2014: 20 drugs
| Tamsulosin | 1,416 | $29,987 | $21 |
| Avodart | 129 | $28,637 | $222 |
| Vesicare | 110 | $28,089 | $255 |
| Finasteride | 929 | $14,787 | $16 |
| Enablex | 33 | $9,789 | $297 |
| Oxybutynin Chloride Er | 149 | $6,484 | $44 |
| Bicalutamide | 169 | $5,250 | $31 |
| Oxybutynin Chloride | 124 | $3,938 | $32 |
| Nitrofurantoin Mono-Macro | 68 | $3,895 | $57 |
| Flomax | 11 | $3,857 | $351 |
| Doxazosin Mesylate | 104 | $3,480 | $33 |
| Alfuzosin Hcl Er | 124 | $3,054 | $25 |
| Jalyn | 12 | $1,766 | $147 |
| Ciprofloxacin | 212 | $1,171 | $6 |
| Terazosin | 87 | $1,030 | $12 |
| Trimethoprim | 78 | $1,012 | $13 |
| Potassium Citrate Er | 12 | $901 | $75 |
| Hydrocodone-Acetaminophen | 23 | $406 | $18 |
| Sulfamethoxazole-Trimethoprim | 35 | $155 | $4 |
| Amitriptyline | 11 | $71 | $6 |
2013: 20 drugs
| Avodart | 153 | $31,790 | $208 |
| Vesicare | 141 | $31,363 | $222 |
| Tamsulosin | 1,161 | $23,873 | $21 |
| Finasteride | 653 | $15,032 | $23 |
| Enablex | 40 | $10,130 | $253 |
| Bicalutamide | 179 | $7,155 | $40 |
| Jalyn | 21 | $4,146 | $197 |
| Nitrofurantoin Mono-Macro | 56 | $3,976 | $71 |
| Alfuzosin | 122 | $3,648 | $30 |
| Flomax | 12 | $3,589 | $299 |
| Oxybutynin Chloride Er | 69 | $3,471 | $50 |
| Oxybutynin Chloride | 135 | $2,331 | $17 |
| Doxazosin Mesylate | 81 | $1,922 | $24 |
| Terazosin | 113 | $1,335 | $12 |
| Ciprofloxacin | 180 | $931 | $5 |
| Trimethoprim | 49 | $665 | $14 |
| Sulfamethoxazole-Trimethoprim | 37 | $194 | $5 |
| Hydrocodone-Acetaminophen | 44 | $181 | $4 |
| Megestrol Acetate | 21 | $169 | $8 |
| Amitriptyline | 15 | $45 | $3 |
Money from drug and device companies
$388 in 2025
| 2025 | 4 | 10 | None | $388 |
| 2024 | 3 | 10 | None | $227 |
| 2023 | 4 | 12 | None | $647 |
| 2022 | 2 | 9 | None | $175 |
| 2021 | 3 | 9 | None | $235 |
| 2020 | 3 | 5 | None | $94 |
| 2019 | 4 | 12 | None | $353 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Rybrevant | $146 | 4 payments
|
| Ferring Pharmaceuticals | Adstiladrin | $134 | 1 payment
|
| C. R. Bard Inc. & Subsidiaries | Bard Urinary Drainage Bag | $91 | 4 payments
|
| Accord Healthcare | Camcevi | $17 | 1 payment
|
See all 10 published payments
| C. R. Bard Inc. & Subsidiaries | Meals · 2025-10-29 | Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire | $21 |
| C. R. Bard Inc. & Subsidiaries | Meals · 2025-09-10 | Bard Urinary Drainage Bag | $22 |
| C. R. Bard Inc. & Subsidiaries | Meals · 2025-08-26 | Bard Urinary Drainage Bag | $34 |
| C. R. Bard Inc. & Subsidiaries | Meals · 2025-07-23 | Bard Urinary Drainage Bag | $14 |
| Janssen Biotech | Meals · 2025-07-07 | Erleada | $9 |
| Ferring Pharmaceuticals | Meals · 2025-04-25 | Adstiladrin | $134 |
| Janssen Biotech | Meals · 2025-04-24 | Rybrevant | $117 |
| Janssen Biotech | Meals · 2025-04-10 | Erleada | $10 |
| Accord Healthcare | Meals · 2025-04-08 | Camcevi | $17 |
| Janssen Biotech | Meals · 2025-02-05 | Erleada | $9 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $227
| Astellas Pharma US | Xtandi | $142 | 7 payments
|
| Janssen Biotech | Erleada | $46 | 2 payments
|
| Ethicon US | N/A | $39 | 1 payment
|
2023: $647
| Astellas Pharma US | Myrbetriq | $391 | 9 payments
|
| Edap Technomed | None | $125 | 1 payment
|
| Boston Scientific | None | $109 | 1 payment
|
| Janssen Biotech | Erleada | $21 | 1 payment
|
2022: $175
| Astellas Pharma US | Xtandi | $146 | 8 payments
|
| Abbvie | Lupron Depot | $29 | 1 payment
|
2021: $235
| AbbVie | Lupron Depot | $130 | 5 payments
|
| Janssen Biotech | Erleada | $65 | 2 payments
|
| Astellas Pharma US | Xtandi | $40 | 2 payments
|
2020: $94
| Astellas Pharma US | Xtandi | $42 | 2 payments
|
| AbbVie | Lupron Depot | $37 | 2 payments
|
| Janssen Biotech | Erleada | $15 | 1 payment
|
2019: $353
| Astellas Pharma US | Xtandi | $169 | 6 payments
|
| Janssen Biotech | Erleada | $129 | 4 payments
|
| Pfizer | Xtandi | $30 | 1 payment
|
| Allergan | Botox | $24 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1851341655
- Licence
- CA G87196California G87196: Current · expires 2027-09-30
- Trained
- University of Alabama School of Medicine, 1993
- Group
- El Camino Health Medical Network LLC · County of Santa Clara
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 75 N Bascom Ave Ste 210, San Jose, CA, 95128
- NPI first listed
- 2006-05-11
- NPI last updated
- 2012-10-01
This is when the NPI record was last certified, not a medical board exam.